ArticleInternational journal of hematology2026
Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fostamatinib was approved in Japan in December 2022 for primary immune thrombocytopenia (ITP). Given the limited clinical trial data, post-marketing surveillance (PMS) was conducted in Japan to collect safety and effectiveness data for fostamatinib. This interim analysis of PMS collected data between April 2023 and April 2025. Most of the 489 patients in the safety analysis set had received ≥ 3 treatment lines. Approximately 70% used fostamatinib with glucocorticoids and/or a thrombopoietin receptor agonist. Adverse drug reactions (ADRs) were reported in 49.5% (serious ADRs in 8.6%). The most common ADRs were diarrhoea (20.0%), hypertension (15.7%), hepatic function abnormal (9.6%), liver disorders (4.9%), and neutrophil count decreased (4.1%). Safety analysis revealed no major differences in the frequency of ADRs, including those of special interest, by combination treatment(s). Median platelet count increased at 2 weeks of treatment and remained above 50,000/μL thereafter, regardless of the ITP treatment combination. Further, complete response (platelet count ≥ 100,000/μL) was observed in 135 of 309 patients at 3 months and 128 of 241 patients at 6 months under continuous fostamatinib use. The results of this real-world PMS revealed no new safety concerns and support the effectiveness of fostamatinib in patients with primary ITP.
Indexed as
Identifiers
42530846What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.